medigraphic.com
ISSN 0016-3813 (Print)

2012, Number 2

<< Back Next >>

Gac Med Mex 2012; 148 (2)

Prevalencia del síndrome metabólico (SM) en pacientes con diabetes mellitus de tipo 1 (DM1)

Ferreira HA, Vargas OG, González VB, Mercado AM, Molina AM

Language: Spanish
References: 24
Page: 137-143
PDF size: 88.77 Kb.


ABSTRACT

Background: Double diabetes is the association between type 1 diabetes mellitus (DM1) and metabolic syndrome (MS). The prevalence of hypertension, dyslipidemia, central obesity and macrovascular complications has increased in DM1 patients, regardless glycemic control. Objective: To determine the prevalence of MS in patients with DM1. Methods: We performed a descriptive cross-sectional study of clinical characteristics of DM1 patients. Biochemical and anthropometric parameters were determined and the presence of hypertension, dyslipidemia and central obesity were assessed. MS was defined according to American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) and National Cholesterol Education Program: Adult Treatment Panel III (NCEP:ATPIII) criteria. Results: For this study 130 patients were evaluated (66% women) with a median age of 29.5 years (interquartile range [RI]: 22-36) and disease evolution of 12 years (RI: 7-17). 47% had dyslipidemia, 23% hypoalphalipoproteinemia, 11% hypertrigliceridemia and 13% both pathologies. Additionally 64% had high level of low-density lipoprotein cholesterol (C-LDL) and 21% had hypertension. According to AHA/NHLBI criteria, 37.5% (with three parameters) and 14% (more than three parameters) of patients were estimated to have MS. On the other hand, using NCEP:ATPIII criteria 25% (three parameters) and 11.5% (more than three parameters) had MS. Patients with DM1 and MS were older, heavier and had greater body mass index (BMI) and waist circumference. Conclusion: The presence of MS in patients with DM1 is evident in our study. There are no differences in glycosylated hemoglobin or insulin doses between groups with and without MS.


REFERENCES

  1. Gillespie K. Type 1 diabetes: pathogenesis and prevention. CMAJ. 2006;175:165-70.

  2. Wherret DK, Daneman D. Prevention of type 1 diabetes. Endocrinol Metab Clin North Am. 2009;38:777-90.

  3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol. JAMA. 2001;285:2486-97.

  4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.

  5. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735-52.

  6. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes. 1982;31:795-801.

  7. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (noninsulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1982; 23:313-9.

  8. Teupe B, Bergis K. Epidemiological evidence for «double diabetes». Lancet. 1991;337:361-2.

  9. Chillarón JJ, Goday A, Pedro-Botet J. Síndrome metabólico, diabetes mellitus tipo 1 y resistencia a la insulina. MedClin (Barc). 2008;130: 466-71.

  10. Arai K, Yokoyama H, Okuguchi F, et al. Association between Body Mass Index and core components of Metabolic Syndrome in 1486 patients with type 1 Diabetes Mellitus in Japan (JDDT13). Endocr J. 2008;55:1025-32.

  11. Rodrigues TC, Canani LH, Gross JL. Metabolic Syndrome, Insulin Resistance and Cardiovascular Disease in Type-1 Diabetes Mellitus. Arq Bras Cardiol. 2010;94:125-30.

  12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.

  13. Meijer JW, Bosma E, Lefrandt J, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care. 2003;26:697-701.

  14. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39:S1-266.

  15. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinic diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-82.

  16. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care. 2006;29:2528-38.

  17. Báez MS, Novik V, Alegría F, Cardemil F, Riveros R, Bofill L. Síndrome metabólico en un grupo de pacientes diabéticos tipo 1. ¿Una nueva variedad de diabetes? Rev Med Chile. 2009;137:888-93.

  18. Chillarón JJ, Flores-Le-Roux JA, Goday A, et al. Metabolic Syndrome and Type-1 Diabetes Mellitus: Prevalence and Associated Factors. Rev Esp Cardiol. 2010;63:423-9.

  19. Clausen TD, Mathiesen ER, Hansen T, et al. Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab. 2009;94:2464-70.

  20. The Metascreen Writing Committee. The metabolic Syndrome is a risk indicator of microvascular and macrovascular complications in Diabetes. Diabetes Care. 2006;29:2701-7.

  21. Pambianco G, Costacou T, Orchard TJ. The prediction of major outcomes of type 1 diabetes: a 12 year prospective evaluation of three separate definitions of the metabolic syndrome, and their components and estimated glucose disposal rate: the Pittsburg Epidemiology of Diabetes Complications Study experience. Diabetes Care. 2007;30: 1248-54.

  22. Momesso DP, Bussade I, Lima GA, Fonseca LP, Russo LA, Kupfer R. Body composition, metabolic syndrome and insulin resistance in type 1 diabetes mellitus. Arq Bras Endocrinol Metabol. 2011;55:189-93.

  23. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: «double diabetes» in the Diabetes Control and Complications Trial. Diabetes Care. 2007;30:707-12.

  24. Momesso DP, Bussade I, Epifanio MA, Schettino CD, Russo LA, Kupfer R. Increased epicardial adipose tissue in type 1 diabetes is associated with central obesity and metabolic syndrome. Diabetes Res Clin Pract. 2011;91:47-53.




2020     |     www.medigraphic.com